Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.24.1.1.u2
Revenues from Contracts and Significant Customers (Tables)
3 Months Ended
Mar. 31, 2024
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Three Months Ended March 31, 

    

2024

    

2023

Revenue

Qbrexza

$

5,017

$

4,094

Accutane

5,819

4,648

Amzeeq

755

1,193

Zilxi

273

314

Other / legacy product revenue

1,166

1,916

Collaboration revenue

181

Revenue – related party

 

 

35

Other revenue

 

48

Total net revenue

$

13,030

$

12,429